Bristol-Myers Squibb (BMY) – FDA
-
Bristol-Myers Squibb (BMY) and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies
-
Bristol-Myers Squibb's (BMY) KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Local
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BMY Stock Lookup